Read More

CG Oncology Announces Data From The Phase 3 BOND-003 Study Evaluating The Efficacy And Safety Of Cretostimogene Monotherapy, Demonstrated 75.2% Complete Response Rate In High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT

CGON

Read More

Why Restaurant Chain El Pollo Loco’s Shares Are Soaring Today

El Pollo Loco Holdings showcases robust growth, reporting a 1.4% year-on-year sales increase to $116.15 million in first-quarter FY24, surpassing analyst expectations. With a 5.1% rise in system-wide comparable restaurant sales and a 24% surge in operating income to $9.7 million, the company demonstrates resilience and profitability in its performance.

LOCO